story of the week
Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Oral Semaglutide Meets Efficacy Endpoints as First Oral GLP-1
- Efficacy and Safety of Oral Semaglutide With Flexible Dose Adjustment vs Sitagliptin in Type 2 Diabetes
- Efficacy and Safety of Oral Semaglutide in Patients With Type 2 Diabetes and Moderate Renal Impairment
- Cardiovascular Safety of Oral Semaglutide in Patients With Type 2 Diabetes
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Oral Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes
N. Engl. J. Med 2019 Jun 11;[EPub Ahead of Print], M Husain, AL Birkenfeld, M Donsmark, K Dungan, FG Eliaschewitz, DR Franco, OK Jeppesen, I Lingvay, O Mosenzon, SD Pedersen, CJ Tack, M Thomsen, T Vilsbøll, ML Warren, SC BainFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.